Stockscreener 앱 받기
111.66
0.28%
0.31
시장 영업 전:
112.00
0.34
+0.30%
Biontech Se Adr 주식(BNTX)의 최신 뉴스
BioNTech’s Promising Phase II Study on BNT327 for Small-cell Lung Cancer - The Globe and Mail
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
Genmab and BioNTech’s GEN1042 Study: A Promising Step in Cancer Treatment - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game-Changer? - TipRanks
BioNTech’s BNT327 Study: A New Hope for Advanced Lung Cancer Treatment - TipRanks
Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer? - The Globe and Mail
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
BioNTech ADR Earns RS Rating Upgrade - inkl
BioNTech’s Strategic Moves and Financial Outlook - The Globe and Mail
BioNTech SE Earnings Call: Strategic Growth Amid Challenges - TipRanks
BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer? - TipRanks
Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech Earnings: Guidance Reiterated; Incremental Progress in Clinical Trials - Morningstar
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 - GlobeNewswire Inc.
BioNTech’s BNT327 Study: A New Hope for Lung Cancer Treatment? - TipRanks
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update04.08.25News - Ariva
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - The Globe and Mail
BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday - Defense World
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - Yahoo Finance
Cancer Vaccine Market Research Service Featuring the Top 5 Developers and Pipeline Activities - GlobeNewswire Inc.
Best Momentum Stocks to Buy for July 29th - Yahoo Finance
New Strong Buy Stocks for July 29th - Yahoo Finance
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Acquired by Kestra Private Wealth Services LLC - Defense World
Cerity Partners LLC Invests $357,000 in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
BioNTech’s Promising Study on Pancreatic Cancer Treatment: Market Implications - TipRanks
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - TipRanks
BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks
BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks
BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva
BioNTech’s DYNASTY-Breast02 Study: A New Hope for Metastatic Breast Cancer? - TipRanks
OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks
BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks
BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest
Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - The Globe and Mail
Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks
Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks
BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
3.39%
2.10%
자본화:
|
볼륨(24시간):